Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | PNP | P00491 | 3/20 | 0.48 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.48 |
| ▸ | TK1 | P04183 | 2/20 | 0.47 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | EDNRA | P25101 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | VCP | P55072 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9124915 | 1.00 | ADORA3 (0.52) | ADORA3PNPSTING1TK1HPRT1 | |
| SCHEMBL26196873 | 0.88 | ADORA3 (0.48) | ADORA3PNPSTING1TK1HPRT1 | |
| SCHEMBL18519687 | 0.86 | HPRT1 (0.45) | ADORA3PNPSTING1HPRT1BLM | |
| SCHEMBL20324729 | 0.84 | HPRT1 (0.44) | ADORA3PNPSTING1HPRT1BLM | |
| SCHEMBL20324648 | 0.84 | HPRT1 (0.48) | ADORA3PNPSTING1HPRT1 | |
| SCHEMBL20324698 | 0.83 | HPRT1 (0.43) | ADORA3PNPSTING1HPRT1BLM | |
| SCHEMBL20324562 | 0.83 | HPRT1 (0.49) | PNPHPRT1 | |
| SCHEMBL22381969 | 0.81 | ADORA3 (0.52) | ADORA3PNPSTING1TK1HPRT1 | |
| SCHEMBL21942766 | 0.81 | ADORA3 (0.52) | ADORA3PNPSTING1TK1HPRT1 | |
| SCHEMBL6517600 | 0.81 | ADORA3 (0.56) | ADORA3PNPSTING1TK1HPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0525106-A4 | 2',3'-DIDEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AGENTS | — | 1993-04-21 | — | — | EP | claimed |
| EP-0525106-A1 | 2',3'-DIDEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AGENTS | SOUTHERN RESEARCH INSTITUTE (US) | 1993-02-03 | — | — | EP | claimed |
| US-5128458-A | 2',3'-dideoxy-4'-thioribonucleosides as antiviral agents | SOUTHERN RESEARCH INSTITUTE (US) | 1992-07-07 | — | — | US | claimed |
| WO-1991016333-A1 | 2',3'-DIDEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AGENTS | SOUTHERN RESEARCH INSTITUTE (US) | 1991-10-31 | — | — | WO | claimed |
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-08 | — | — | US | disclosed |
| US-7875733-B2 | Nucleosides; RNA interference; gene expression inhibition; for use in therapeutic, diagnostic, and research applications involving gene silencing | ISIS PHARMACEUTICALS, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-5478928-A | Useful as antiviral agents in the treatment and prevention of AIDS | SOUTHERN RESEARCH INSTITUTE (US) | 1995-12-26 | — | — | US | disclosed |
| EP-0525106-A4 | 2',3'-DIDEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AGENTS | — | 1993-04-21 | — | — | EP | disclosed |
| EP-0525106-A1 | 2',3'-DIDEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AGENTS | SOUTHERN RESEARCH INSTITUTE (US) | 1993-02-03 | — | — | EP | disclosed |
| US-5128458-A | 2',3'-dideoxy-4'-thioribonucleosides as antiviral agents | SOUTHERN RESEARCH INSTITUTE (US) | 1992-07-07 | — | — | US | disclosed |
| WO-1991016333-A1 | 2',3'-DIDEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AGENTS | SOUTHERN RESEARCH INSTITUTE (US) | 1991-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | ADORA3 110/4885PNP 305/4885STING1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.